An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Among patients with myelodysplastic syndrome, long noncoding RNA
KIAA0125 may predict poorer overall survival and leukemia-free survival.
Researchers reviewed the challenges and future developments in ICI combination therapies for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromes.
Although other flow cytometry–based prognostic scores have been proposed in the setting of MDS, their complexity has limited their clinical use.
There may be no relapse-free survival or overall survival benefits with posttransplant azaciditine in patients with high-risk AML or MDS.
Among some patients with myelodysplastic syndrome, gene expression signatures appear to be predictive of response and primary resistance to azacitidine.
With the exception of alloSCT and iron chelation therapy, many guideline treatments may not improve survival among patients with myelodysplastic syndrome.
Researchers studied survival in reduced-intensity conditioning HSCT vs non-HSCT approaches for older, transplantation-eligible patients with advanced MDS.
The first-in-class imetelstat demonstrated clinically meaningful red blood cell transfusion independence rates in lower-risk MDS, according to results of a phase 2 trial.
A graft-vs-MDS effect of graft-vs-host disease has been observed for some patients with acute leukemia post-HSCT, but has been less well studied in those with MDS.
Researchers aimed to determine iron and oxidative stress characteristics and their effects on survival in patients with lower-risk myelodysplastic syndrome.
A study with murine models suggests that quercetin may induce autophagy in myelodysplastic bone marrow among patients with myelodysplastic syndrome.
For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.
As transplantation-related complications are high among patients with MDS, determining which patients will benefit from HSCT is essential.
Premyelodysplastic syndrome blood kinetics are linked to both disease risk and overall survival.
The administration of cedazuridine with decitabine prevents the degradation of decitabine by CDA in the gastrointestinal tract and liver increasing its systemic exposure.
Novel treatment options are needed to improve outcomes for patients with
TP53-mutated myeloid neoplasms.
Immunomodulator indoleamine-2,3-dioxygenase may be a promising predictor and therapeutic target for patients with higher-risk myelodysplastic syndromes.
Given the prevalence, the IWG-PM evaluated available evidence to determine whether
SF3B1-mutated MDS should be recognized as a distinct disease subtype.
Transfusion independence for at least 8 weeks was observed in 38% of patients receiving luspatercept compared with 13% of patients receiving placebo.
Rates of nonrelapse mortality and 3-year overall survival were similar between patients 55 to 64 years old and patients 65 years or older who underwent transplantation.
Researchers conducted a meta-analysis to determine whether iron chelation therapy leads to improved overall and leukemia-free survival in patients with myelodysplastic syndrome.
Transfusion dependence, very high-risk cytogenetics, and high serum ferritin were identified as risk factors for death in a multivariable analysis.
Researchers identified 8 combinations of genes that could be used to predict whether a patient will respond to treatment with hypomethylating agents.
Nonmyeloablative conditioning was associated with increased nonrelapse mortality and shorter overall survival compared with reduced-intensity conditioning.
Myelodysplastic syndromes display a high degree of heterogeneity, making it difficult to establish a standard of care for patients.
Patients who received androgen therapy demonstrated improvements in erythroid, platelet, and neutrophil measures.
The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.
A variety of immune pathways mediate the pathogenesis of myelodysplastic syndromes, suggesting that the immune system may be a feasible therapeutic target.
Compared with hypomethylating agents, intensive chemotherapy was associated with higher overall response and complete remission rates.
Patients who experienced reactivation of Epstein-Barr virus also experienced inferior relapse-free survival and increased incidence of relapse.
Results from a systematic review and meta-analysis published in Critical Reviews in Oncology/Hematology indicated there was no association between mutations in SF3B1 and overall survival (OS) in patients with myelodysplastic syndrome (MDS). Mutations in the SF3B1 gene are the most common mutations in MDS, though the prognostic implications of these mutations are unclear. In this…
Prolonged-release administration of anagrelide resulted in a noninferior decrease in mean platelet levels compared with immediate-release administration.
There is a pressing need to develop novel therapeutic strategies for patients with myelodysplastic syndrome who are ineligible for transplantation.
The current set of standardized treatment response criteria was most recently revised in 2006 and had many shortcomings when applied to clinical trials.
Up to 65% of patients with myelodysplastic syndrome experience comorbid thrombocytopenia.
Immunosuppressive therapy is used sparingly due to the operational challenges in administration and prediction of patient benefit.
The presence of persistent disease-related mutations 30 days after ASCT for myelodysplastic syndrome was associated with higher risk of disease progression.
In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.
A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.
What is the concern behind PARP inhibitors and leukemia?
Smoking may slightly increase the risk for myelodysplastic syndromes, but alcohol consumption may be significantly protective against MDS.
The US Food and Drug Administration granted orphan drug designation to DSP-7888 for myelodysplastic syndrome.
The results of this study suggest that RIC may be an alternative to MAC, particularly for patients of low cytogenetic risk.
Based on the results of this study, an alternative to HCT should be considered for patients with CK and mutations in TP53 or the RAS pathway.
Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.
Eltrombopag was well-tolerated, significantly raised platelet counts, and reduced bleeding events among patients with MDS and severe thrombocytopenia.